Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,078
archived clinical trials in
Major Depression Disorder (MDD)

Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study to Evaluate the Efficacy and Safety of Brexpiprazole (1 and 3 mg/Day) as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Status: Enrolling
Updated:  12/31/1969
US001
mi
from
National City, CA
Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study to Evaluate the Efficacy and Safety of Brexpiprazole (1 and 3 mg/Day) as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Status: Enrolling
Updated: 12/31/1969
US001
mi
from
National City, CA
Click here to add this to my saved trials
Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study to Evaluate the Efficacy and Safety of Brexpiprazole (1 and 3 mg/Day) as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Status: Enrolling
Updated:  12/31/1969
US008
mi
from
Orlando, FL
Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study to Evaluate the Efficacy and Safety of Brexpiprazole (1 and 3 mg/Day) as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Status: Enrolling
Updated: 12/31/1969
US008
mi
from
Orlando, FL
Click here to add this to my saved trials
Brain Inflammation in Major Depressive Disorder Background
Brain Inflammation In Major Depressive Disorder
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Brain Inflammation in Major Depressive Disorder Background
Brain Inflammation In Major Depressive Disorder
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Nuedexta in Treatment-Resistant Major Depression
Targeting the NMDA Glutamate Receptor as Novel Antidepressant Strategy: A Pilot Clinical Trial of Nuedexta in Treatment-Resistant Major Depression
Status: Enrolling
Updated:  12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Nuedexta in Treatment-Resistant Major Depression
Targeting the NMDA Glutamate Receptor as Novel Antidepressant Strategy: A Pilot Clinical Trial of Nuedexta in Treatment-Resistant Major Depression
Status: Enrolling
Updated: 12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms
Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms
Status: Enrolling
Updated:  12/31/1969
New York State Psychiatric Institute
mi
from
New York, NY
Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms
Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms
Status: Enrolling
Updated: 12/31/1969
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
Low Field Magnetic Stimulation for Treatment Resistant Depression
The Effect of Low Field Magnetic Stimulation on Resting State Networks in Major Depressive Disorder
Status: Enrolling
Updated:  12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Low Field Magnetic Stimulation for Treatment Resistant Depression
The Effect of Low Field Magnetic Stimulation on Resting State Networks in Major Depressive Disorder
Status: Enrolling
Updated: 12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders
Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders
Status: Enrolling
Updated:  12/31/1969
Ralph H. Johnson VA Medical Center, Charleston, SC
mi
from
Charleston, SC
Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders
Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders
Status: Enrolling
Updated: 12/31/1969
Ralph H. Johnson VA Medical Center, Charleston, SC
mi
from
Charleston, SC
Click here to add this to my saved trials
Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder
Interventional, Open-label, Long-term Extension Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  12/31/1969
US008
mi
from
Orlando, FL
Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder
Interventional, Open-label, Long-term Extension Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 12/31/1969
US008
mi
from
Orlando, FL
Click here to add this to my saved trials
Pilot Study Assessing Computerized Cognitive Behavioral Therapy for Depression
Pilot Study Assessing Computerized Cognitive Behavioral Therapy for Depression
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
Pilot Study Assessing Computerized Cognitive Behavioral Therapy for Depression
Pilot Study Assessing Computerized Cognitive Behavioral Therapy for Depression
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Get Moving and Get Well - Pilot Study
Get Moving and Get Well: A Behavioral Activation Program for Veterans With SMI
Status: Enrolling
Updated:  12/31/1969
Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR
mi
from
North Little Rock, AR
Get Moving and Get Well - Pilot Study
Get Moving and Get Well: A Behavioral Activation Program for Veterans With SMI
Status: Enrolling
Updated: 12/31/1969
Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR
mi
from
North Little Rock, AR
Click here to add this to my saved trials
Imaging Dopamine Release in Depression
Ventrostriatal Dopamine Release and Reward Motivation in MDD
Status: Enrolling
Updated:  12/31/1969
New York State Psychiatric Institute
mi
from
New York, NY
Imaging Dopamine Release in Depression
Ventrostriatal Dopamine Release and Reward Motivation in MDD
Status: Enrolling
Updated: 12/31/1969
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
A Randomized Controlled Trial of PCIT-ED for Preschool Depression
A Randomized Controlled Trial of PCIT-ED for Preschool Depression
Status: Enrolling
Updated:  12/31/1969
Early Emotional Development Program
mi
from
Saint Louis, MO
A Randomized Controlled Trial of PCIT-ED for Preschool Depression
A Randomized Controlled Trial of PCIT-ED for Preschool Depression
Status: Enrolling
Updated: 12/31/1969
Early Emotional Development Program
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Developing New Clinical Management Strategies
Developing New Clinical Management Strategies for Antidepressant Treatments
Status: Enrolling
Updated:  12/31/1969
New York State Psychiatric Institute
mi
from
New York, NY
Developing New Clinical Management Strategies
Developing New Clinical Management Strategies for Antidepressant Treatments
Status: Enrolling
Updated: 12/31/1969
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)
Status: Enrolling
Updated:  12/31/1969
Alkermes Investigational Site
mi
from
Jacksonville, FL
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)
Status: Enrolling
Updated: 12/31/1969
Alkermes Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)
Status: Enrolling
Updated:  12/31/1969
Alkermes Investigational Site
mi
from
Orlando, FL
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)
Status: Enrolling
Updated: 12/31/1969
Alkermes Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)
Status: Enrolling
Updated:  12/31/1969
Alkermes Study Site
mi
from
Atlanta, GA
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)
Status: Enrolling
Updated: 12/31/1969
Alkermes Study Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)
Status: Enrolling
Updated:  12/31/1969
Alkermes Investigational Site
mi
from
Staten Island, NY
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)
Status: Enrolling
Updated: 12/31/1969
Alkermes Investigational Site
mi
from
Staten Island, NY
Click here to add this to my saved trials
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)
Status: Enrolling
Updated:  12/31/1969
Alkermes Investigational Site
mi
from
Dayton, OH
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)
Status: Enrolling
Updated: 12/31/1969
Alkermes Investigational Site
mi
from
Dayton, OH
Click here to add this to my saved trials
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)
Status: Enrolling
Updated:  12/31/1969
Alkermes Investigational Site
mi
from
Allentown, PA
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)
Status: Enrolling
Updated: 12/31/1969
Alkermes Investigational Site
mi
from
Allentown, PA
Click here to add this to my saved trials
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)
Status: Enrolling
Updated:  12/31/1969
Alkermes Investigational Site
mi
from
Bellevue, WA
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)
Status: Enrolling
Updated: 12/31/1969
Alkermes Investigational Site
mi
from
Bellevue, WA
Click here to add this to my saved trials
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)
Status: Enrolling
Updated:  12/31/1969
Alkermes Investigational Site
mi
from
Halifax,
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)
Status: Enrolling
Updated: 12/31/1969
Alkermes Investigational Site
mi
from
Halifax,
Click here to add this to my saved trials
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)
Status: Enrolling
Updated:  12/31/1969
Alkermes Investigational Site
mi
from
Saint Charles, MO
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)
Status: Enrolling
Updated: 12/31/1969
Alkermes Investigational Site
mi
from
Saint Charles, MO
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Birmingham Psychiatry Pharmaceutical Studies, Inc.
mi
from
Birmingham, AL
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Birmingham Psychiatry Pharmaceutical Studies, Inc.
mi
from
Birmingham, AL
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Catalina Research Institute
mi
from
Chino, CA
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Catalina Research Institute
mi
from
Chino, CA
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Synergy Research Center
mi
from
Escondido, CA
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Synergy Research Center
mi
from
Escondido, CA
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Pharmacology Research Institute
mi
from
Los Alamitos, CA
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Pharmacology Research Institute
mi
from
Los Alamitos, CA
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
North County Research
mi
from
Oceanside, CA
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
North County Research
mi
from
Oceanside, CA
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
CITRIALS
mi
from
Riverside, CA
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
CITRIALS
mi
from
Riverside, CA
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Stanford School of Medicine
mi
from
Stanford, CA
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Stanford School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Viking Clinical Research
mi
from
Temecula, CA
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Viking Clinical Research
mi
from
Temecula, CA
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Elite Clinical Trials
mi
from
Wildomar, CA
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Elite Clinical Trials
mi
from
Wildomar, CA
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
MCB Clinical Research Centers
mi
from
Colorado Springs, CO
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
MCB Clinical Research Centers
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Howard University Hospital Mental Health Clinic
mi
from
Washington,
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Howard University Hospital Mental Health Clinic
mi
from
Washington,
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Sarkis Clinical Trials
mi
from
Gainesville, FL
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Sarkis Clinical Trials
mi
from
Gainesville, FL
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Clinical Neuroscience Solutions Healthcare
mi
from
Jacksonville, FL
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Clinical Neuroscience Solutions Healthcare
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Clinical Research Trials of Florida, Inc.
mi
from
Tampa, FL
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Clinical Research Trials of Florida, Inc.
mi
from
Tampa, FL
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Stedman Clinical Trials
mi
from
Tampa, FL
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Stedman Clinical Trials
mi
from
Tampa, FL
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Janus Center for Psychiatric Research
mi
from
West Palm Beach, FL
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Janus Center for Psychiatric Research
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Atlanta Institute of Medicine and Research
mi
from
Atlanta, GA
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Atlanta Institute of Medicine and Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Meridian Clinical Research, LLC
mi
from
Savannah, GA
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Meridian Clinical Research, LLC
mi
from
Savannah, GA
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Carman Research
mi
from
Smyrna, GA
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Carman Research
mi
from
Smyrna, GA
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Behavioral Healthcare Associates
mi
from
Schaumburg, IL
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Behavioral Healthcare Associates
mi
from
Schaumburg, IL
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
The Institute of Psychiatric Research
mi
from
Indianapolis, IN
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
The Institute of Psychiatric Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Kansas University Medical Center- Clinical Trials Unit
mi
from
Wichita, KA
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Kansas University Medical Center- Clinical Trials Unit
mi
from
Wichita, KA
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Pharmasite Research
mi
from
Baltimore, MD
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Pharmasite Research
mi
from
Baltimore, MD
Click here to add this to my saved trials
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Hospital
mi
from
Baltimore, MD
Genomics Used to Improve DEpression Decisions
A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials